A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab Therapy in Patients with Selected Incurable Cancers

Protocol No
CORVUS-CPI-444-001
Principal Investigator
Matthew Riese
Phase
I
Summary
The purpose of this study is to find out whether an investigational (experimental) drug called CPI-444 can be used, either on its own, or in combination with another investigational drug called atezolizumab (also known as MPDL3280A) on you and the specific type of cancer you have. Your bodys immune system has a certain natural ability to prevent or withstand cancer growth. However, tumors can resist the immune system by increasing adenosine, (which occurs naturally in all cells of the body) which reduces the ability of the immune system to attack tumors. CPI-444 is a small molecule that may help your immune system to prevent or stop the growth of tumors by blocking a location on your cells (receptor) that adenosine stimulates and thus stopping the effect of adenosine. Atezolizumab is an antibody (a large, Y-shaped protein used by your body's immune system to identify and neutralize foreign objects such as bacteria, viruses, and tumor cells) that affects your immune system by blocking the PD-L1 pathway. The PD-L1 pathway is involved in decreasing your body s natural immune response to fight cancer. By blocking the PD-L1 pathway, atezolizumab may help your immune system stop or reverse the growth of tumors. Giving CPI-444 in combination with atezolizumab may have additional anti-tumor effects that could potentially shrink your tumor. The combination of CPI-444 with atezolizumab has not been tested together in humans before, but both drugs have been used in humans independent of each other. We want to find out the best dose of CPI-444, both on its own and in combination with atezolizumab and what effects, good and/or bad, either CPI-444 on its own or in combination with atezolizumab has on you and your cancer.
Description
CPI-444 as Single Agent or in Combination with Atezolizumab Therapy in Patients with Incurable Cancer
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: